-
Tytuł:
-
Therapeutic effects of recombinant SPLUNC1 on Mycoplasma ovipneumoniae-infected Argali hybrid sheep.
-
Autorzy:
-
Li J; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
Liu H; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
Zhao N; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
Wang J; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
Yang Y; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China.
Sun Y; College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang 832003, China. Electronic address: .
-
Źródło:
-
Research in veterinary science [Res Vet Sci] 2020 Dec; Vol. 133, pp. 174-179. Date of Electronic Publication: 2020 Sep 12.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : British Veterinary Association
Original Publication: Oxford.
-
MeSH Terms:
-
Glycoproteins/*therapeutic use
Pneumonia, Mycoplasma/*veterinary
Recombinant Proteins/*therapeutic use
Sheep Diseases/*drug therapy
Animals ; Enzyme-Linked Immunosorbent Assay/veterinary ; Glycoproteins/genetics ; Interleukins/blood ; Lung/microbiology ; Lung/pathology ; Mycoplasma ovipneumoniae ; Pneumonia, Mycoplasma/drug therapy ; Pneumonia, Mycoplasma/pathology ; Real-Time Polymerase Chain Reaction/veterinary ; Sheep ; Sheep Diseases/pathology ; Treatment Outcome
-
Contributed Indexing:
-
Keywords: Argali hybrid sheep; Interleukin; Mycoplasma ovipneumoniae; SPLUNC1
-
Substance Nomenclature:
-
0 (Glycoproteins)
0 (Interleukins)
0 (Recombinant Proteins)
-
Entry Date(s):
-
Date Created: 20200929 Date Completed: 20210224 Latest Revision: 20210224
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.rvsc.2020.09.010
-
PMID:
-
32992128
-
Clinical therapeutic and immunoregulatory effects of recombinant SPLUNC1 protein (rSPLUNC1) were evaluated in Mycoplasma ovipneumoniae (Mo)-infected Argali hybrid sheep (AHS). Group A contained six Bashibai sheep (BS) and groups B-D contained six AHS each. All sheep were manually infected with Mo. Five days post-infection, rSPLUNC1 from BS and AHS was injected intratracheally into group C and D animals; physiological saline was administered to groups A and B. Serum IL-5, IL-6, and IL-9 were quantified by ELISA. After sacrificing the sheep, lung tissues were extracted for pathological examination. The qPCR was used to quantify Mo load in the lungs and evaluate therapeutic efficacy. Serum IL-5, IL-6, and IL-9 concentrations increased during early infection stages in all groups but were significantly lower in groups A, C, and D than in group B on days 14 and 21. On day 21, IL-5 concentrations were lower in group A than in groups C and D. IL-6 concentration in groups A, C, and D was significantly lower than that in group B, and that in groups C and D was significantly lower than that in group A. Mean mycoplasma pneumonia histopathology scores were significantly lower in groups C and D than in group B, and Mo load in group C and D lung tissue decreased significantly compared to that in group B. Intratracheal injection of rSPLUNC1 into Mo-infected sheep decreased the cytokine levels and alleviated clinical symptoms with no mortality. rSPLUNC1 had significant therapeutic effects on Mo-infected AHS and can regulate pro-inflammatory cytokines.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
